JP2025539841A5 - - Google Patents
Info
- Publication number
- JP2025539841A5 JP2025539841A5 JP2025529969A JP2025529969A JP2025539841A5 JP 2025539841 A5 JP2025539841 A5 JP 2025539841A5 JP 2025529969 A JP2025529969 A JP 2025529969A JP 2025529969 A JP2025529969 A JP 2025529969A JP 2025539841 A5 JP2025539841 A5 JP 2025539841A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- sequence described
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2022/134067 | 2022-11-24 | ||
| CN2022134067 | 2022-11-24 | ||
| CN2023107003 | 2023-07-12 | ||
| CNPCT/CN2023/107003 | 2023-07-12 | ||
| PCT/IB2023/061813 WO2024110905A1 (en) | 2022-11-24 | 2023-11-22 | Anti-cea antibody drug conjugates and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025539841A JP2025539841A (ja) | 2025-12-09 |
| JP2025539841A5 true JP2025539841A5 (https=) | 2026-02-18 |
Family
ID=88978400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025529969A Pending JP2025539841A (ja) | 2022-11-24 | 2023-11-22 | 抗ｃｅａ抗体薬物コンジュゲート及びその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250115677A1 (https=) |
| EP (1) | EP4622677A1 (https=) |
| JP (1) | JP2025539841A (https=) |
| KR (1) | KR20250111207A (https=) |
| CN (2) | CN120187458A (https=) |
| AR (1) | AR131143A1 (https=) |
| AU (1) | AU2023383923A1 (https=) |
| CL (1) | CL2025001502A1 (https=) |
| CO (1) | CO2025008154A2 (https=) |
| IL (1) | IL320971A (https=) |
| MX (1) | MX2025006057A (https=) |
| TW (1) | TW202434306A (https=) |
| WO (1) | WO2024110905A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120957753A (zh) * | 2023-03-23 | 2025-11-14 | 广州百济神州生物制药有限公司 | 生物活性结合物、其制备方法和其用途 |
| AR133125A1 (es) * | 2023-06-29 | 2025-08-27 | Beigene Switzerland Gmbh | Conjugados bioactivos, método de preparación y uso de estos |
| CN121568721A (zh) * | 2023-06-29 | 2026-02-24 | 广州百济神州生物制药有限公司 | 生物活性缀合物、其制备方法和其用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| KR101860963B1 (ko) | 2010-04-23 | 2018-05-24 | 제넨테크, 인크. | 이종다량체 단백질의 생산 |
| PE20141017A1 (es) | 2011-03-02 | 2014-08-25 | Roche Glycart Ag | Anticuerpos del cea |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| CN105026430B (zh) | 2012-11-28 | 2025-03-25 | 酵活英属哥伦比亚有限公司 | 工程化免疫球蛋白重链-轻链对及其用途 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| CA2924398A1 (en) * | 2013-11-05 | 2015-05-14 | Immunomedics, Inc. | Humanized anti-ceacam5 antibody and uses thereof |
| CA3244731A1 (en) | 2014-05-28 | 2025-11-29 | Zymeworks Bc Inc. | Modified antigen binding polypeptide constructs and uses thereof |
| EP3359576B1 (en) | 2015-10-08 | 2024-12-25 | Zymeworks BC Inc. | Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof |
| AU2021335257A1 (en) * | 2020-09-04 | 2023-03-09 | Merck Patent Gmbh | Anti-CEACAM5 antibodies and conjugates and uses thereof |
| CA3219672A1 (en) * | 2021-05-21 | 2022-11-24 | Liang QU | Anti-cea and anti-cd137 multispecific antibodies and methods of use |
| IL313805A (en) | 2021-12-28 | 2024-08-01 | Beigene Switzerland Gmbh | Drug antibody conjugates |
-
2023
- 2023-11-22 TW TW112145240A patent/TW202434306A/zh unknown
- 2023-11-22 EP EP23814251.7A patent/EP4622677A1/en active Pending
- 2023-11-22 CN CN202380077578.4A patent/CN120187458A/zh active Pending
- 2023-11-22 AR ARP230103150A patent/AR131143A1/es unknown
- 2023-11-22 KR KR1020257021001A patent/KR20250111207A/ko active Pending
- 2023-11-22 JP JP2025529969A patent/JP2025539841A/ja active Pending
- 2023-11-22 AU AU2023383923A patent/AU2023383923A1/en active Pending
- 2023-11-22 CN CN202511471839.8A patent/CN121177510A/zh active Pending
- 2023-11-22 WO PCT/IB2023/061813 patent/WO2024110905A1/en not_active Ceased
- 2023-11-22 IL IL320971A patent/IL320971A/en unknown
-
2024
- 2024-11-07 US US18/940,225 patent/US20250115677A1/en active Pending
-
2025
- 2025-05-20 CL CL2025001502A patent/CL2025001502A1/es unknown
- 2025-05-23 MX MX2025006057A patent/MX2025006057A/es unknown
- 2025-06-18 CO CONC2025/0008154A patent/CO2025008154A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025539841A5 (https=) | ||
| JP2020019787A5 (https=) | ||
| BR112021011014A2 (pt) | Anticorpos anti-claudina e usos destes | |
| JP2024059609A5 (https=) | ||
| JP2020509027A5 (https=) | ||
| JP2017506234A5 (https=) | ||
| JP2023089195A (ja) | グリピカン３抗体およびそのコンジュゲート | |
| JP2023547323A5 (https=) | ||
| JP2010535713A5 (https=) | ||
| JP2008526234A5 (https=) | ||
| JP2020525542A5 (https=) | ||
| JP2012522513A5 (https=) | ||
| JP2025523382A (ja) | 抗ｂ７ｈ３抗体－薬物複合体及びその使用 | |
| JP2017534256A5 (https=) | ||
| CN107735093A (zh) | Cd123抗体和其结合物 | |
| JP2017534253A5 (https=) | ||
| RU2011144141A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2025183307A5 (https=) | ||
| JP2024501894A5 (https=) | ||
| JP2017522861A5 (https=) | ||
| JP2024533356A5 (https=) | ||
| RU2017112884A (ru) | Иммуноконъюгаты, содержащие антитела против her2 и пирролбензодиазепины | |
| JP5948525B1 (ja) | 癌のための併用療法 | |
| JP2020500834A (ja) | マクロファージ刺激タンパク質受容体（又はＲＯＮ（Ｒｅｃｅｐｔｅｕｒ ｄ′Ｏｒｉｇｉｎｅ Ｎａｎｔａｉｓ））抗体及びその使用 | |
| JP2024523422A (ja) | 抗腫瘍化合物およびその応用 |